SCHEMBL3589092

SCHEMBL3589092

O=C(CCC(F)(F)F)CCC(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.31
NAMPT P43490 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25309973 0.87 CES1 (0.39)
SCHEMBL15346753 0.87 ACE (0.48)
SCHEMBL15512429 0.85 PLA2G4A (0.40)
SCHEMBL3950064 0.84 HTT (0.33) HTT
SCHEMBL4257794 0.83 TDP1 (0.45)
SCHEMBL8744846 0.83 GABRR1 (0.46)
SCHEMBL21022853 0.83 FAAH (0.32)
SCHEMBL6338324 0.83
SCHEMBL10584705 0.83 FAAH (0.45)
SCHEMBL25307541 0.81 PLA2G4A (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109111914-A A kind of ultraviolet enhanced film of rare earth compounding 合肥工业大学 2019-01-01 CN claimed
US-12595408-B2 Photochromic compound, naphthol derivative, curable composition, optical article, lens, and eyeglasses TOKUYAMA CORPORATION (JP) 2026-04-07 US disclosed
US-20250101294-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES TOKUYAMA CORPORATION (JP) 2025-03-27 US disclosed
EP-4471018-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES TOKUYAMA CORPORATION (JP) 2024-12-04 EP disclosed
CN-118574819-A Photochromic compound, naphthol derivative, curable composition, optical article, lens and spectacles 株式会社德山 2024-08-30 CN disclosed
WO-2023140186-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES 株式会社トクヤマ 2023-07-27 WO disclosed
WO-2022196523-A1 FLUORINE-CONTAINING COMPOUND AND CONTRAST AGENT TDK株式会社 2022-09-22 WO disclosed
CN-109705839-A A kind of rare-earth europium hybrid mesoporous luminescent material of terpyridyl derivative functionalization and its preparation method and application 河北科技大学 2019-05-03 CN disclosed
CN-106011485-B From the method for extracting scandium oxide in waste residue containing scandium 潮州三环(集团)股份有限公司 2018-11-16 CN disclosed
CN-108610483-A A kind of high-purity dimethicone of resistance to oxidation and its synthetic method 广州盛泰诺新材料科技有限公司 2018-10-02 CN disclosed
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 US disclosed
US-20100048623-A1 PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-02-25 US disclosed
EP-2013171-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE Merck Sharp & Dohme Limited (GB) 2009-01-14 EP disclosed
WO-2008130581-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-10-30 WO disclosed
WO-2007125364-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2007-11-08 WO disclosed
US-6136847-A Water-soluble trioxanes as potent and safe antimalarial agents JOHNS HOPKINS UNIVERSITY (US) 2000-10-24 US disclosed
WO-2000059501-A1 WATER-SOLUBLE TRIOXANES AS POTENT AND SAFE ANTIMALARIAL AGENTS JOHNS HOPKINS UNIVERSITY (US) 2000-10-12 WO disclosed
US-5932591-A C3 substituted trioxanes useful as antiparasitic drugs JOHNS HOPKINS UNIVERSITY (US) 1999-08-03 US disclosed
US-4633023-A Fluoroacrylate ester, polymer thereof, and process of making the same GEO-CENTERS, INC. (US) 1986-12-30 US disclosed
US-4578508-A Fluoroacrylate ester, polymer thereof, and process of making the same GEO-CENTERS, INC. (US) 1986-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595408-B2 Photochromic compound, naphthol derivative, curable composition, optical article, lens, and eyeglasses CRYAA, CRYZ, CRY2 HTT 2122/4885NAMPT 3219/4885
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GCGR, GPR65 HTT 1931/4885NAMPT 523/4885
US-20250101294-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES NAP1L1, CRYAA, CRYZ HTT 1900/4885NAMPT 702/4885
US-20100048623-A1 PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, PSEN1, BACE2 HTT 552/4885NAMPT 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.